Injectable PLGA Microspheres for Linear Progestogen Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing progestogen formulations, particularly those using PLGA microspheres, exhibit non-linear cumulative drug release profiles with either an initial burst or lag phase, which are unsuitable for therapies requiring daily intramuscular injections over a specific period.
Innovation Solution
Development of PLGA microspheres encapsulating progestogen drugs with a biodegradable polymer composition, designed to achieve a linear cumulative release profile without an initial burst or lag phase, suitable for parenteral administration, specifically for subcutaneous or intramuscular use, with a controlled release duration of at least 6 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If PLGA microspheres are used for sustained-release progesterone formulations, then dosing frequency is reduced and patient compliance is improved, but non-linear release profiles with initial burst or lag phase occur which are unsuitable for daily intramuscular injection therapies
Solution Approach 1:
The patent modifies the PLGA polymer parameters (molecular weight, lactide-glycolide ratio, chain end groups) to control the release profile. Specifically, using PLGA with molecular weight of 5-50 kD and lactide-glycolide ratio of 50:50 to 75:25 achieves linear cumulative release without burst or lag phases, resolving the contradiction between sustained-release capability and release profile linearity
Solution Approach 2:
The patent employs composite PLGA polymer structures with specific molecular weight distributions and copolymer compositions. The use of carboxyl-terminated or ester-terminated PLGA polymers with controlled molecular weights (5-50 kD) creates a composite material system that delivers linear release profiles while maintaining sustained-release characteristics
2Reliability
If oil solution formulations are used for intramuscular progesterone administration, then high serum levels are achieved reliably, but severe pain and hypersensitivity reactions occur due to local tissue disruption
Solution Approach 1:
The patent introduces PLGA microspheres as an intermediary carrier system between the progesterone drug and the injection site. The microspheres encapsulate the hydrophobic progesterone and degrade gradually to release the drug, eliminating the need for irritant oil solutions while maintaining reliable serum level achievement through controlled release over 6-14 days
3Ease of operation
If oral progesterone administration is used, then convenience is improved, but gastrointestinal absorption is slow and hepatic metabolism is high which limits plasma levels and drug efficacy
Solution Approach 1:
The patent replaces the gastrointestinal absorption pathway (oral administration) with a parenteral microsphere injection system. The PLGA microspheres deliver progesterone directly into the injection site, bypassing first-pass hepatic metabolism and gastrointestinal absorption limitations, thereby achieving higher and more reliable plasma levels while maintaining ease of administration through simple intramuscular or subcutaneous injection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microspheres provide a linear cumulative drug release profile, ensuring consistent drug delivery over 6 to 14 days without initial burst or lag phase, enhancing therapeutic efficacy and patient compliance.
Implementation Method 1
biodegradable polymer composition comprising a PLGA polymer
Implementation Method 2
linear cumulative release profile
Data Source
AI summary
The present invention relates to injectable microspheres and formulations comprising the microspheres for controlled release of progestogen hormones.